Stocks and Investing Stocks and Investing
Fri, January 20, 2023
Thu, January 19, 2023

Silvan Tuerkcan Maintained (TSHA) at Buy with Decreased Target to $6 on, Jan 19th, 2023


Published on 2024-10-28 01:00:26 - WOPRAI, Silvan Tuerkcan
  Print publication without navigation


Silvan Tuerkcan of JMP Securities, Maintained "Taysha Gene Therapies, Inc." (TSHA) at Buy with Decreased Target from $20 to $6 on, Jan 19th, 2023.

Silvan has made no other calls on TSHA in the last 4 months.



There are 6 other peers that have a rating on TSHA. Out of the 6 peers that are also analyzing TSHA, 1 agrees with Silvan's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Salveen Richter of "Goldman Sachs" Downgraded from Strong Buy to Hold and Decreased Target to $3 on, Wednesday, November 9th, 2022


These are the ratings of the 5 analyists that currently disagree with Silvan


  • Yanan Zhu of "Wells Fargo" Maintained at Buy with Decreased Target to $10 on, Wednesday, January 4th, 2023
  • Geulah Livshits of "Chardan Capital" Maintained at Strong Buy with Decreased Target to $16 on, Wednesday, November 9th, 2022
  • Gil Blum of "Needham" Maintained at Strong Buy with Decreased Target to $16 on, Wednesday, November 9th, 2022
  • Whitney Ijem of "Canaccord Genuity" Initiated at Strong Buy and Held Target at $16 on, Tuesday, November 8th, 2022
  • Jack Allen of "Baird" Maintained at Buy with Decreased Target to $21 on, Wednesday, October 26th, 2022

Contributing Sources